Environment and Renewable Energy Industry in Latvia

Enterprise Europe Network (Profile: TRUK20200710001)

Short description of advertisement: 
Technical cooperation sought for exploitation of a novel real-time blood propofol sensor for integration into a variety of applications

A UK company has developed a novel biosensor for measuring blood propofol concentration in real-time incorporated into an analyte recovery platform that does not require blood withdrawal. 

Under technical cooperation agreements, partner organisations will contribute to and influence the further development of the technology to facilitate successful integration into established or newly developed devices.

The company is led by a senior hospital doctor and a leading clinical researcher with an international reputation. Both have a track record of successfully commercialising patient safety products. The company was established specifically to address a clinical need in hospital based anaesthetic and sedation practice. The need is currently unmet by any other product(s).

Approximately 4 million patients in the UK and 400 million globally receive a general anaesthetic each year. In 90% of cases this is achieved with the administration of anaesthetic gases. These are greenhouse gases and highly damaging to the environment as well as having unwanted side effects for patients. Their use persists, however, partly because the concentration being delivered to each patient can be measured. 

For more than 20 years an alternative has existed; total intravenous anaesthesia (TIVA) using a drug called propofol. TIVA has many advantages for patients including a far lower risk of nausea, smoother recovery, and greater chance of long-term survival for patients with cancer. In addition, it is tens of thousands of times less damaging to the environment than anaesthetic gases. 

One of the main reasons given by anaesthetists for not using it more often is the lack of technology to measure in real-time the concentration of propofol in the patient's blood stream, an equivalent facility to that which is available for gaseous anaesthesia. Enquiry of Patient and Public Involvement groups shows surprise that such monitoring is not already in use.

In addition, propofol is widely used in intensive care units where it is administered by intravenous infusion to sedate patients undergoing invasive therapies such as assisted ventilation.

The company has been partly funded by the UK government (using its Innovate UK platform) to develop a novel real-time blood propofol sensor for incorporation into a system that does not require blood withdrawal.  The output from the monitoring system can be transmitted to a variety of different displays ranging from a stand-alone propofol monitor to incorporation into existing equipment such as processed EEG depth of anaesthesia monitors. Here it will offer an invaluable additional data source with which to assess the adequacy of anaesthesia. Additionally, the data can be utilised to provide TIVA pumps delivering propofol to patients with real-time information about what concentration is actually being achieved and thus offer a personalised, dynamic feedback loop. 

Working with international biosensor experts at a UK university, the company has developed and patented a novel biosensor based on cyclic voltammetry in which the activity of an immobilised enzyme draws electrons from an electrode resulting in a measured current proportional to the propofol concentration. Studies of sensor response to repeated use over three days (far longer than any surgical procedure) show good stability (see Fig.1)

The biosensor has been developed to Technology Readiness Level (TRL) 4; ‘functioning lab prototype' 

Collaborating partners are now sought for the further development and utilisation of the novel real-time blood propofol concentration monitor. 

In addition, collaborating partners are sought for the integration of the sensor in to existing near point of care monitoring equipment utilised in intensive care units such as blood gas analysers or other equipment used to analyse blood samples at the bed side. 

The conclusion of these partnering opportunities will be a product or products developed to TRL 8 or beyond where partners possess full commercialisation capability.



For more information please contact Enterprise Europe Network Latvia.

Contact person: 
Enterprise Europe Network Latvia
Contact languages: 
United Kingdom
Perses Street 2, Riga, LV-1442, Latvia
info [at] een [dot] lv
Proposal valid till: 
Friday, 30 July, 2021